Nodal recurrence following axillary downstaging with neoadjuvant chemotherpay + omission of ALND

Omitting axillary lymph node dissection in breast cancer patients after neoadjuvant chemotherapyПодробнее

Can we forego axillary lymph node dissection in early breast cancer?Подробнее

Management of axilla after neo-adjuvant treatmentПодробнее

Management of axilla after neo-adjuvant treatmentПодробнее

Practical approach to the management of the axilla after neoadjuvant chemotherapyПодробнее

Axillary dissection vs radiation for residual nodal disease after neoadjuvant systemic therapyПодробнее

Educational Sessions: "Refining axillary management after neoadjuvant chemotherapy - what does..."Подробнее

Evidence-based approach to lymph node assessment and targeted axillary dissectionПодробнее

SLNB after neoadjuvant chemotherapyПодробнее

Adjuvant Therapy | 2023 Best of Breast ConferenceПодробнее

Evolving role of axillary surgery in breast cancer after neoadjuvant chemotherapyПодробнее

The role of axillary dissection to determine nodal burden to inform systemic therapy recommendationsПодробнее

Axillary Nodes After Neoadjuvant Treatment: An Update from SABCS 2016Подробнее

Difference Between Sentinel Biopsy and Axillary Dissection Following Neoadjuvant TherapyПодробнее

Educational Sessions: "Can radiation replace ALND after + SLNB"Подробнее

TAXIS: axillary dissection to determine nodal burden to inform systemic therapy in node-positive BCПодробнее

Axillary Nodes After Neoadjuvant Treatment: An Update from SABCS 2016Подробнее

Dr. Mamounas on Recurrence and Tailoring Radiotherapy Following Neoadjuvant ChemotherapyПодробнее

Axillary Management of Node-Positive Breast Cancer after Neoadjuvant ChemotherapyПодробнее